Table 2.
Characteristics of patients with biliary disease.
| Trefle® (n = 14) |
POCS (n = 20) |
p Value | |
|---|---|---|---|
| Age, years | 70.5 (53–85) | 71 (47–84) | 0.779 *1 |
| Sex, male/female | 8/6 | 11/9 | 0.901 *2 |
| Malignancy/Benign | 8/6 | 10/10 | 0.681*2 |
| Location (perihilar/distal) | 3/11 | 9/11 | 0.293 *2 |
| Length of stricture, mm | 18.4 (8.8–42.0) | 16.0 (1.2–46.0) | 0.431 *1 |
| Acute cholangitis (presence/absence) | 1/13 | 3/17 | 0.874 *2 |
| Total bilirubin, mg/dL | 1.1 (0.6–25.4) | 1.3 (0.3–14.8) | 0.972 *1 |
| Tumor marker (serum) | |||
| CEA, ng/mL | |||
| Malignant | 2.3 (1.2–4.8) | 2.5 (1.4–8.3) | 0.307 *3 |
| Benign | 2.0 (1.4–4.2) | 1.9 (1.6–3.1) | 0.609 *3 |
| CA19-9, U/mL | |||
| Malignant | 76.5 (0.8–11985.0) | 52.5 (17.8–577.6) | 0.271 *3 |
| Benign | 7.7 (7.1–13.6) | 7.6 (1.6–71.6) | 0.545 *3 |
Values are presented as number or median (range). Abbreviations: POCS, peroral cholangioscopy; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9. *1 p value: Mann–Whitney U test. *2 p value: Chi-square test. *3 p value: Student’s t-test.